- Home
- CRBU vs DOUG Comparison
CRBU vs DOUG Comparison
Compare CRBU & DOUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRBU
- DOUG
- Stock Information
- Founded
- CRBU 2011
- DOUG 1911
- Country
- CRBU United States
- DOUG United States
- Employees
- CRBU N/A
- DOUG N/A
- Industry
- CRBU Medicinal Chemicals and Botanical Products
- DOUG Building operators
- Sector
- CRBU Health Care
- DOUG Real Estate
- Exchange
- CRBU Nasdaq
- DOUG Nasdaq
- Market Cap
- CRBU 165.8M
- DOUG 161.5M
- IPO Year
- CRBU 2021
- DOUG N/A
- Fundamental
- Price
- CRBU $1.78
- DOUG $3.11
- Analyst Decision
- CRBU Strong Buy
- DOUG
- Analyst Count
- CRBU 3
- DOUG 0
- Target Price
- CRBU $6.67
- DOUG N/A
- AVG Volume (30 Days)
- CRBU 729.3K
- DOUG 503.2K
- Earning Date
- CRBU 11-05-2025
- DOUG 11-05-2025
- Dividend Yield
- CRBU N/A
- DOUG N/A
- EPS Growth
- CRBU N/A
- DOUG N/A
- EPS
- CRBU N/A
- DOUG N/A
- Revenue
- CRBU $9,121,000.00
- DOUG $1,034,406,000.00
- Revenue This Year
- CRBU $9.23
- DOUG $17.61
- Revenue Next Year
- CRBU N/A
- DOUG N/A
- P/E Ratio
- CRBU N/A
- DOUG N/A
- Revenue Growth
- CRBU N/A
- DOUG 8.69
- 52 Week Low
- CRBU $0.66
- DOUG $1.35
- 52 Week High
- CRBU $3.00
- DOUG $3.20
- Technical
- Relative Strength Index (RSI)
- CRBU 46.16
- DOUG 66.95
- Support Level
- CRBU $1.72
- DOUG $2.58
- Resistance Level
- CRBU $1.94
- DOUG $2.95
- Average True Range (ATR)
- CRBU 0.11
- DOUG 0.15
- MACD
- CRBU -0.01
- DOUG 0.03
- Stochastic Oscillator
- CRBU 26.53
- DOUG 88.32
About CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.
About DOUG Douglas Elliman Inc.
Douglas Elliman Inc is a real estate company. It offers sales, rentals, and new development to mortgages and title insurance, among other services related to real estate. Business is engaged in two operating segments Real Estate Brokerage and Corporate and other. The firm generates income from Commission and other brokerage revenue from existing home sales, Commission and other brokerage income from development marketing, Property management revenue and Title fees. It derives revenue from Real Estate Brokerage segment.